Mounjaro and Weight Loss in Japan: What the Research Actually Says About Tirzepatide

In clinical trials, tirzepatide produced average weight loss of up to about 21% over 72 weeks, but alongside diet and exercise guidance, with side effects to manage and a specific off-label context in Japan.

GLP-1 medications have become one of the biggest developments in medical weight management in recent years.

But Mounjaro is slightly different from medications that act only on GLP-1.

Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors. In Japan, the current Mounjaro prescribing information classifies it as a long-acting GIP/GLP-1 receptor agonist.¹

Clinical trials have shown substantial reductions in body weight with tirzepatide. But the headline numbers only tell part of the story.

How does tirzepatide actually work? How much weight did people lose in clinical studies? Does diet still matter? What about protein and exercise? And how much can treatment cost in Japan?

Here is what the evidence actually says.

What is Mounjaro?

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine.

Unlike medications that target the GLP-1 receptor alone, tirzepatide activates receptors for two incretin hormones:

• GIP: glucose-dependent insulinotropic polypeptide
• GLP-1: glucagon-like peptide-1

Japan's current Mounjaro prescribing information officially describes tirzepatide as a long-acting GIP/GLP-1 receptor agonist.¹

These pathways influence blood glucose regulation, appetite and food intake.

A randomized trial investigating eating behavior found that tirzepatide reduced calorie intake, hunger, food cravings and the tendency to overeat compared with placebo. At week 3, participants receiving tirzepatide consumed approximately 525 fewer kcal during an ad-libitum test meal than those receiving placebo.²

That doesn't mean Mounjaro simply “burns fat.”

A large part of its effect appears to come from changing the biological signals surrounding hunger, fullness and food intake, which can make eating fewer calories easier for some people.

How much weight can you lose with tirzepatide?

One of the most important studies is the SURMOUNT-1 trial, published in The New England Journal of Medicine.

Researchers enrolled 2,539 adults with overweight or obesity who did not have diabetes and randomly assigned them to tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks.³

Average body-weight changes at 72 weeks were approximately:

Source: SURMOUNT-1.³

At the 15 mg dose, 57% of participants who had evaluable data lost at least 20% of their starting body weight, compared with approximately 3% receiving placebo.³

These are substantial results, but they need context.

They are averages from a controlled clinical trial, not a prediction of what one individual will lose.

Someone weighing 100 kg should not interpret a 20.9% study average as a guarantee that they will reach 79.1 kg.

Individual response can vary considerably.

The important part people often leave out

The participants in SURMOUNT-1 weren't simply given tirzepatide and told to carry on with their normal lifestyle.

Everyone in the study also received lifestyle guidance.

Participants were encouraged to follow a diet creating approximately a:

500 kcal daily energy deficit

and perform at least:

150 minutes of physical activity each week.

They also received repeated lifestyle counselling during the study.^3,4

That matters.

The famous “up to around 20% average weight loss” result should not be interpreted as:

Injection = 20% weight loss regardless of lifestyle.

The clinical evidence is closer to:

tirzepatide + reduced calorie intake + physical activity + ongoing support.

How should you approach weight loss while using tirzepatide?

Medication can help reduce appetite, but there is still a job to do.

1. Don't try to eat as little as possible

Having dramatically less appetite can sound like the perfect diet.

It isn't necessarily.

Eating too little can also mean consuming inadequate:

• protein
• vitamins
• minerals
• fibre
• essential fats
• overall nutrition

The goal should generally be a sustainable calorie deficit, rather than trying to survive on the smallest possible amount of food.

The 500 kcal/day deficit used in SURMOUNT-1 is useful context because the participants producing those impressive results weren't instructed to stop eating. They were encouraged to follow a balanced reduced-calorie diet.⁴

A person's appropriate calorie intake depends on factors including body size, age, activity and medical status, so calorie targets should be individualized rather than copied blindly from an online calculator.

2. Prioritize protein and muscle preservation

There is another number that receives much less attention than the headline weight-loss figures.

Not every kilogram lost is body fat.

A body-composition substudy of SURMOUNT-1 used DXA scans to examine what participants actually lost.

Among participants receiving tirzepatide, researchers found that approximately:

75% of the lost weight was fat mass
25% was lean mass.⁵

That doesn't mean 25% of someone's muscle disappears. “Lean mass” includes more than skeletal muscle.

But it does demonstrate why preserving lean tissue deserves attention during large amounts of weight loss.

This is one reason adequate dietary protein and resistance exercise are commonly emphasized during pharmacological weight-management treatment.

Instead of thinking only:

“How fast is the scale dropping?”

a better question is:

“How much fat can I lose while maintaining as much strength and lean tissue as possible?”

3. Include resistance training

Cardio and walking are useful.

But resistance training deserves a seat at the table too.

Exercise and nutrition reviews examining GLP-1-based weight management emphasize resistance exercise and sufficient high-quality protein as strategies for supporting muscle preservation during substantial weight loss.⁶

This doesn't mean someone needs to become a bodybuilder.

Resistance exercise could include:

• weight training
• machines
• resistance bands
• bodyweight exercises
• other progressive strength training

The important part is providing muscles with a reason to stick around while body weight is falling.

4. Keep moving

The SURMOUNT-1 trial targeted at least 150 minutes of physical activity per week.⁴

That works out to roughly:

30 minutes, five days per week.

Walking can absolutely count toward that target depending on intensity.

For many people, a practical routine might combine regular walking or other aerobic activity with strength training several times per week.

The medication can make appetite management easier.

It doesn't replace the benefits of being physically active.

5. Don't increase the dose yourself

This is important.

More tirzepatide does not automatically mean better treatment.

According to the current Japanese prescribing information for Mounjaro, treatment for its approved indication begins at 2.5 mg once weekly, followed by an increase to 5 mg after four weeks. Further dose adjustments are made at intervals of at least four weeks depending on the patient's response and tolerability.¹

The prescribing information specifically notes that dose reduction or delaying dose escalation should be considered when gastrointestinal side effects make treatment difficult to tolerate.¹

So:

“I didn't lose enough this week, so I'll increase my dose”

is not a sensible dosing strategy.

Dose changes should be decided with the prescribing physician.

What side effects can Mounjaro cause?

Gastrointestinal side effects are among the most commonly reported problems with tirzepatide.

The current Japanese Mounjaro prescribing information lists gastrointestinal reactions occurring in at least 5% of patients including:¹

• nausea
• vomiting
• diarrhea
• constipation
• abdominal pain
• indigestion
• reduced appetite

Japanese clinical-trial data also show that gastrointestinal symptoms can be particularly relevant while the dose is being increased.⁷

There are less common but potentially serious risks as well.

The Japanese prescribing information includes warnings concerning conditions including:¹

• acute pancreatitis
• gallbladder and biliary disease
• severe allergic reactions
• ileus, including intestinal obstruction
• hypoglycemia, particularly in combination with certain diabetes medications

Weight loss is probably better viewed as long-term management

One of the most interesting tirzepatide studies looked at what happened when treatment stopped.

The SURMOUNT-4 trial, published in JAMA, initially treated participants with tirzepatide for 36 weeks.

Participants had lost an average of 20.9% of their body weight during that initial treatment period.⁸

Researchers then randomized participants either to continue tirzepatide or switch to placebo.

Between weeks 36 and 88:

• people continuing tirzepatide lost another 5.5%
• people switched to placebo regained approximately 14.0%⁸

That doesn't mean every patient needs medication forever.

It does demonstrate something important:

Losing weight and maintaining weight loss are two different problems.

Long-term nutrition, physical activity and medical follow-up matter even when medication has helped produce the initial weight loss.

Important: Mounjaro and Zepbound are not the same indication in Japan

There is an important regulatory distinction that is often blurred online.

Mounjaro and Zepbound contain the same active ingredient: tirzepatide.

But their approved uses in Japan are different.

According to Eli Lilly Japan:⁹

Mounjaro
Approved indication

Type 2 diabetes

Zepbound
Approved indications include

Obesity under defined eligibility criteria, and moderate-or-greater obstructive sleep apnea under specified conditions

For the obesity indication, Zepbound's Japanese eligibility criteria include patients with relevant obesity-related health conditions who have not achieved sufficient results through diet and exercise and who meet specified BMI criteria.⁹

This distinction matters.

Using Mounjaro specifically for weight reduction in someone without its approved Japanese indication constitutes off-label use in Japan.

Treatment should therefore involve proper medical assessment and informed discussion with a physician.

How much does Mounjaro cost in Japan?

Unlike a standard retail product, there isn't one universal self-pay price for Mounjaro.

Prices can differ substantially between clinics based on:

• dose
• consultation fees
• shipping
• subscription requirements
• introductory discounts
• minimum purchase periods
• cancellation conditions

This makes comparisons surprisingly messy.

elife's current introductory Mounjaro pricing

At the time of writing in September 2026, elife's official online shop lists a plan containing:

Mounjaro 2.5 mg × 4 pens

First month

¥9,980

Second month onward

¥19,980

The promotional plan states that cancellation becomes available after receiving the second order.¹⁰

The exact terms should always be checked before purchasing because promotional pricing can change. See the current plan on shop.elife.clinic.

Is elife one of the cheapest Mounjaro options in Japan?

There is actually some outside data supporting that claim, with an important qualification.

A Japanese Mounjaro price-comparison site updated in September 2026 compared 21 online services using their published prices for Mounjaro 2.5 mg × 4 pens.

In that comparison, the lowest confirmed first-month price was elife: ¥9,980.¹¹

The comparison reported a range of approximately ¥9,980 to ¥27,665 among the 21 services reviewed.¹¹

It also clearly notes that elife's ¥9,980 is an introductory price, with the cited plan increasing to ¥19,980 from the second month.¹¹

That distinction is important.

It would be misleading to simply say “elife is the cheapest Mounjaro clinic in Japan.”

A more accurate statement is:

In a September 2026 comparison of 21 online services, elife's ¥9,980 introductory Mounjaro 2.5 mg plan was the lowest first-month price among the services reviewed.¹¹

Pricing changes frequently, and other clinics may have lower long-term prices, bulk-purchase rates or different treatment structures.

What about elife's ¥3,000 LINE gift card?

elife's official shop currently also displays a promotion offering a ¥3,000 gift card for registering with the official LINE account.¹²

Campaign conditions, eligible products, combination with other discounts and expiration periods can change.

For that reason, anyone considering Mounjaro should confirm whether the current LINE gift-card promotion can be combined with the specific Mounjaro treatment plan they choose rather than simply subtracting ¥3,000 from the advertised medication price.

That gives a much more realistic cost comparison.

What actually helps you get better results from tirzepatide?

Strip away the social-media hype and the evidence points toward a fairly sensible formula:

1. Use medication only under medical supervision.
2. Maintain an appropriate calorie deficit rather than trying to stop eating.
3. Prioritize nutritionally dense foods.
4. Consume adequate protein.
5. Exercise regularly.
6. Include resistance training to help preserve lean tissue.
7. Don't rush dose increases.
8. Treat side effects seriously rather than ignoring them.
9. Think about maintaining the weight loss, not just reaching a target weight.

Tirzepatide can make one particularly difficult part of weight loss, controlling hunger and energy intake, significantly easier for some people.

But the research doesn't really support the idea that lifestyle suddenly becomes irrelevant.

In fact, some of the most impressive tirzepatide results ever published were produced alongside structured diet and physical-activity guidance.^3,4

The bottom line

Tirzepatide is one of the most significant developments in modern obesity research.

In SURMOUNT-1, average weight reduction reached approximately 20.9% after 72 weeks at the 15 mg dose, compared with 3.1% with placebo.³

But those participants also received guidance targeting a 500 kcal daily calorie deficit and at least 150 minutes of physical activity each week.⁴

Body-composition research indicates that most of the weight lost with tirzepatide was fat mass, although lean mass was also lost, making nutrition and resistance exercise relevant considerations.^5,6

And stopping treatment can be followed by substantial weight regain, emphasizing the importance of longer-term weight-management strategies.⁸

For people comparing private treatment costs in Japan, elife currently lists Mounjaro 2.5 mg × 4 pens from ¥9,980 for the first month, rising to ¥19,980 under the cited continuation plan.¹⁰

A September 2026 independent comparison of 21 online services found that ¥9,980 was the lowest introductory one-month price among the services it reviewed.¹¹

elife's official shop also currently advertises a ¥3,000 LINE-registration gift-card promotion, although eligibility and combination with specific prescription plans should be confirmed against the current campaign terms.¹²

Price can make treatment more accessible.

But the cheapest treatment is only useful when the medication is medically appropriate, the patient understands the potential risks and the plan is sustainable beyond the first discounted month.

Medical information notice: This article is for general educational purposes and is not individual medical advice. Tirzepatide is a prescription medicine. Treatment eligibility, dosing, continuation and management of adverse effects should be determined by a qualified physician.